

# AZD8330

**Catalog No: tcsc0217**



## Available Sizes

---

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



## Specifications

---

**CAS No:**

869357-68-6

**Formula:**

$C_{16}H_{17}FIN_3O_4$

**Pathway:**

MAPK/ERK Pathway

**Target:**

MEK

**Purity / Grade:**

>98%

**Solubility:**

10 mM in DMSO

**Alternative Names:**

ARRY-424704;ARRY-704

**Observed Molecular Weight:**

461.23


## Product Description

AZD8330 (ARRY-424704) is a potent, uncompetitive **MEK1/MEK2** inhibitor, with an **IC<sub>50</sub>** of 7 nM.

IC50 & Target: IC50: 7 nM (MEK1/MEK2)<sup>[1]</sup>

**In Vitro:** AZD8330 is a selective allosteric MEK1/ MEK2 inhibitor. Exposing human osteosarcoma cell lines MOS, U2OS, and 143B to a concentration of 0.5 μM of Trametinib, AZD8330 or TAK-733 for 6 hours, leads to loss of ERK phosphorylation indicating effective MEK inhibition. The activity of these three inhibitors is tested using concentration ranges in six osteosarcoma cell lines: MOS, U2OS, KPD, ZK58, 143b and Saos-2. All three inhibitors decrease viability of MOS and U2OS and strongly affect 143b. By contrast, viability of KPD, ZK58 and Saos-2 is not affected by any of the three inhibitors<sup>[2]</sup>.

**In Vivo:** In tumour xenograft models, AZD8330 demonstrates dose-dependent tumour growth inhibition of approximately 90% at tolerated doses (1.0 mg/kg once daily [OD])<sup>[1]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!